SCPS (Scopus BioPharma) Total Payout Ratio: 0.21 (As of Jul. 12, 2026)


What is Scopus BioPharma Total Payout Ratio?

Scopus BioPharma SCPS Total Payout Ratio is 0.21 as of Jul. 12, 2026.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Scopus BioPharma's current Total Payout Ratio is 0.21.

Scopus BioPharma Total Payout Ratio Related Terms

Scopus BioPharma Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Total Payout Ratio Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Payout Ratio
Get a 7-Day Free Trial 0.78 0.66 0.30 0.75 0.00

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.75 -0.02

SCPS vs AMPE, DRMA, SPRC: Total Payout Ratio Comparison

For the Biotechnology subindustry, Scopus BioPharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's Total Payout Ratio falls into.


Scopus BioPharma Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Scopus BioPharma's Total Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -11.715
=0.00

Scopus BioPharma's Total Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + -0.045 + 0) / -2.929
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.21 mean?
Scopus BioPharma (SCPS) has a Total Payout Ratio of 0.21 as of Jul. 12, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Total Payout Ratio too high?
Scopus BioPharma's current Total Payout Ratio is 0.21.
How does Scopus BioPharma's Total Payout Ratio compare to AMPE and DRMA?
Scopus BioPharma's Total Payout Ratio of 0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Total Payout Ratio is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Total Payout Ratio of 0.21. The current Total Payout Ratio is 0.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Total Payout Ratio is 0.21 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.